C

CytomX Therapeutics
D

CTMX

1.09000
USD
-0.01
(-0.91%)
Market Closed
Volume
0
EPS
0
Div Yield
-
P/E
7
Market Cap
85,302,178
OverviewSignalsIdeasNews
Related Instruments
    AMGN
    AMGN
    2.27
    (0.87%)
    263.46 USD
    BIIB
    BIIB
    -0.780
    (-0.53%)
    146.590 USD
    BMY
    BMY
    0.990
    (1.76%)
    57.280 USD
    GILD
    GILD
    1.460
    (1.60%)
    92.570 USD
    LLY
    LLY
    11.01
    (1.45%)
    768.44 USD
    MRK
    MRK
    -1.390
    (-1.40%)
    98.150 USD
    PFE
    PFE
    0.595
    (2.31%)
    26.360 USD
    REGN
    REGN
    -5.64
    (-0.80%)
    702.60 USD
    VRTX
    VRTX
    0.58
    (0.15%)
    397.15 USD
    More
News

Title: CytomX Therapeutics

Sector: Healthcare
Industry: Biotechnology
CytomX Therapeutics Inc is an oncology-focused biopharmaceutical company that is operating in the United States. It is engaged in developing antibody therapeutics based on probody technology platforms. The company's probody technology platform creates proprietary cancer immunotherapies against clinically-validated targets and develops cancer therapeutics. Probody therapeutics are designed to take advantage of conditions in the tumor microenvironment to enhance the tumor-targeting features of an antibody and reduce drug activity in healthy tissues.